Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.

Journal for immunotherapy of cancer - 1 Mar 2021

Ross-Macdonald Petra, Walsh Alice M, Chasalow Scott D, Ammar Ron, Papillon-Cavanagh Simon, Szabo Peter M, Choueiri Toni K, Sznol Mario, Wind-Rotolo Megan

Abstract excerpt

BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunotherapy, factors such as programmed death ligand-1 (PD-L1) status and tumor mutational burden show limited predictive utility in ccRCC. To address this gap, we report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Antigens

Share to CD8 Antigens

Share to Immune Checkpoint Inhibitors

Share to Lymphocytes, Tumor-Infiltrating

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 33658305
DOI: 10.1136/jitc-2020-001506
PMCID: PMC7931766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.PMID 33658305Read ↗

Determinants of anti-PD1 response and resistance in clear cell renal cell carcinomaSemantic proximity Read ↗

Molecular determinants of response to PD-L1 blockade across tumor types.Semantic proximity Read ↗

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.Semantic proximity Read ↗

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapySemantic proximity Read ↗

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.Semantic proximity Read ↗

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escapeSemantic proximity Read ↗

A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinomaSemantic proximity Read ↗

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinomaSemantic proximity Read ↗

Multimodal cell communication networks nominate immunotherapies for RCC subgroups with discrete T cell recruitment or expansionSemantic proximity Read ↗

High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpointsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.